Biomarkers for Alzheimer’s disease. Where we stand and where we are headed

Biomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos

dc.creatorChrem Mendez, Patricio
dc.creatorSurace, Ezequiel
dc.creatorBérgamo, Yanina
dc.creatorCalandri, Ismael
dc.creatorVázquez, Silvia
dc.creatorSevlever, Gustavo
dc.creatorAllegri, Ricardo Francisco
dc.date2020-11-19T19:44:22Z
dc.date2020-11-19T19:44:22Z
dc.date2019
dc.date.accessioned2023-10-03T19:53:40Z
dc.date.available2023-10-03T19:53:40Z
dc.identifierhttps://hdl.handle.net/11323/7372
dc.identifierCorporación Universidad de la Costa
dc.identifierREDICUC - Repositorio CUC
dc.identifierhttps://repositorio.cuc.edu.co/
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9173060
dc.descriptionBiomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos. La enfermedad de Alzheimer (EA) es uno de los mayores flagelos aún no resueltos que acompañan al aumento de la expectativa de vida. El gran cambio de paradigma en los últimos años fue consecuencia de descubrir que el depósito amiloideo se presenta hasta 20 años antes, y la degeneración neurofibrilar hasta 10 años antes, de que aparezca la sintomatología clínica típica de pérdida de memoria. La aparición de los biomarcadores permitió reestructurar el concepto de la EA, intentándose llegar a una definición molecular de la misma casi prescindiendo de la emblemática clínica. Existen distintos tipos de biomarcadores de EA disponibles en nuestro país. Cada uno nos habla de un proceso y un momento distinto de la enfermedad. Aunque su uso clínico aún se encuentra restringido por cuestiones de costos, existen escenarios particulares en donde sí se justifica, casi siempre en relación a presentaciones clínicas atípicas o de comienzo muy temprano. Sin embargo, hoy en día ya nadie discute que son imprescindibles en investigaciones clínicas sobre EA. La incorporación de biomarcadores en la práctica médica ha generado cambios significativos en la intervención terapéutica de los pacientes, incluso en un contexto en el que todavía no hay medicamentos modificadores de la enfermedad.
dc.descriptionAlzheimer disease (AD) is one of the major unresolved health burdens accompanying the increase in life expectancy. The great paradigm shift for this disease has resulted from finding amyloid deposition and neurobrillary degeneration 20 years and 10 years, respectively, prior to onset of the typical clinical memory loss symptoms. The advent of AD biomarkers has enabled a molecular definition of AD, making the clinical definition almost dispensable. Various types of AD biomarkers are available in our country. Each biomarker reflects a particular process and stage of the disease. Although costs restrict their use, the biomarker analysis may be justified in certain clinical scenarios, such as an early onset or an atypical presentation of the disease. Today, the usefulness of biomarkers in AD clinical research is beyond question. Furthermore, the introduction of biomarkers into medical practice has led to significant changes in therapeutic interventions, even in the absence of disease-modifying drugs.
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languagespa
dc.publisherCorporación Universidad de la Costa
dc.relation1. World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. In: https:// www.who.int/mental_health/publications/dementia_report_2012/en/; accessed March 2019.
dc.relation2. Allegri RF, Vázquez S, Sevlever G. Enfermedad de Alzheimer: Nuevos paradigmas, 2da. ed. Buenos Aires: Editorial Polemos, 2018.
dc.relation3. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367: 795-804.
dc.relation4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44.
dc.relation5. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257-62.
dc.relation6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-9.
dc.relation7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9.
dc.relation8. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280-92.
dc.relation9. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535-62.
dc.relation10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-34.
dc.relation11. Niikado M, Chrem-Méndez P, Itzcovich T, et al. Evaluation of cerebrospinal fluid neurofilament light chain as a routine biomarker in a memory clinic. J Gerontol A Biol Sci Med Sci 2019; 74: 442-5.
dc.relation12. Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018; 14: 639-52.
dc.relation13. Hampel H, Vergallo A, Perry G, Lista S. The Alzheimer Precision Medicine Initiative. Alzheimer Precision Medicine Initiative (APMI). J Alzheimers Dis 2019; 68: 1-24.
dc.relation14. Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 2019; 25: 277-83.
dc.relation15. Veitcha DP, Weiner MW, Aiseng PS, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2019; 15: 106-52.
dc.relation16. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain´s default network: anatomy, function, and relevance to disease. Ann NY Acad Sci 2008; 1124: 1-38.
dc.relation17. Allegri RF, Pertierra L, Cohen G, et al. A biological classification for Alzheimer’s disease - Amyloid, Tau and Neurodegeneration (A/T/N): results from the ArgentineAlzheimer’s Disease Neuroimaging Initiative. Int Psychogeriatr 2019; 12: 1-2.
dc.relation18. Parra MA, Baez S, Allegri R, et al. Dementia in Latin America: Assessing the present and envisioning the future. Neurology 2018; 90: 222-31.
dc.relation19. Chrem Méndez P, Cohen G, Russo MJ, et al. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic. Am J Alzheimers Dis Other Demen 2015; 30: 599- 606.
dc.relation20. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321: 1286-94.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.sourceMEDICINA (Buenos Aires)
dc.sourcehttp://www.medicinabuenosaires.com/PMID/31864224.pdf
dc.subjectbiomarcadores de la enfermedad de Alzheimer
dc.subjectetapas preclínicas
dc.subjectneuroimágenes
dc.subjectdiagnóstico molecular
dc.titleBiomarkers for Alzheimer’s disease. Where we stand and where we are headed
dc.titleBiomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos
dc.typeArtículo de revista
dc.typehttp://purl.org/coar/resource_type/c_6501
dc.typeText
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/redcol/resource_type/ART
dc.typeinfo:eu-repo/semantics/acceptedVersion
dc.typehttp://purl.org/coar/version/c_ab4af688f83e57aa


Este ítem pertenece a la siguiente institución